Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 395

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

Open access
Wang, Yongjun, Meng, Xia, Wang, Anxin, Xie, Xuewei, Pan, Yuesong, Johnston, S. Claiborne, Li, Hao, Bath, Philip M., Dong, Qiang, Xu, Anding, Jing, Jing, Lin, Jinxi, Niu, Siying, Wang, Yilong, Zhao, Xingquan, Li, Zixiao, Jiang, Yong, Li, Wei, Liu, Liping, Xu, Jie, Chang, Liguo, Wang, Lihua, Zhuang, Xianbo, Zhao, Jinguo, Feng, Yefang, Man, Honghao, Li, Guozhong, Wang, Baojun·2021·New England Journal of Medicine

Abstract

BACKGROUND: loss-of-function carriers have not been extensively performed. METHODS: loss-of-function alleles. Patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90) and placebo clopidogrel or to receive clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90) and placebo ticagrelor; both groups received aspirin for 21 days. The primary efficacy outcome was new stroke, and the primary safety outcome was severe or moderate bleeding, both within 90 days. RESULTS: A total of 11,255 patients were screened and 6412 patients were enrolled, with 3205 assigned to the ticagrelor group and 3207 to the clopidogrel group. The median age of the patients was 64.8 years, and 33.8% were women; 98.0% belonged to the Han Chinese ethnic group. Stroke occurred within 90 days in 191 patients (6.0%) in the ticagrelor group and 243 patients (7.6%) in the clopidogrel group (hazard ratio, 0.77; 95% confidence interval, 0.64 to 0.94; P = 0.008). Secondary outcomes were generally in the same direction as the primary outcome. Severe or moderate bleeding occurred in 9 patients (0.3%) in the ticagrelor group and in 11 patients (0.3%) in the clopidogrel group; any bleeding occurred in 170 patients (5.3%) and 80 patients (2.5%), respectively. CONCLUSIONS: loss-of-function alleles, the risk of stroke at 90 days was modestly lower with ticagrelor than with clopidogrel. The risk of severe or moderate bleeding did not differ between the two treatment groups, but ticagrelor was associated with more total bleeding events than clopidogrel. (Funded by the Ministry of Science and Technology of the People's Republic of China and others; CHANCE-2 ClinicalTrials.gov number, NCT04078737.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2111749

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 395

Metadata

Authors
Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., Niu, S., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Li, W., Liu, L., Xu, J., Chang, L., Wang, L., Zhuang, X., Zhao, J., Feng, Y., Man, H., Li, G., & Wang, B.
Venue
New England Journal of Medicine
Published
2021-12-30
Volume
385
Issue
27
Pages
2520-2530
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3209828359
Cited by
395
References
19
FWCI
35.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. https://app.cochat.ai/papers/10.1056/nejmoa2111749
The paper
Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., Niu, S., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Li, W., Liu, L., . . . Wang, B. (2021). Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2111749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.